Medical Marijuana Advisory Board Meeting

Thursday, Feb. 13, 2020
10:00am – noon
One of the duties of the Pa Medical Marijuana Advisory Board is to accept and review comments from individuals and organization about medical marijuana. As part of that duty, the Patient and Caregiver Subcommittee of the Advisory Board will seek to gather comments and information from patients, caregivers and other stakeholders through a series of on-line surveys.

Participation in this effort is anonymous and encouraged to help provide valuable information and understanding of how the Pennsylvania Medical Marijuana Program is serving our community and how it can be improved.

Three thousand, two hundred and one people filled out the survey between January 9th and January 28th, when we pulled the data that is being shared in this presentation.
The survey was completed by caregivers for 20 minors under the age of 18. Respondents between the ages 18 and 35 totaled 1270, 1107 respondents were between ages 36 and 50, 614 respondents were between ages 51 and 65, and 184 respondents were 66 or older. Six people skipped this question.
On average, the amount of money I spend on medical marijuana products per month is:

- Less than $100: 15.98%
- $100-$199: 25.06%
- $200-$299: 19.99%
- $300-$499: 21.29%
- $500-$1,000: 14.01%
- Over $1,000: 3.67%
Program Feedback Survey

On average, the amount of money I spend on medical marijuana products per month is:

Region 6

Region 4

Region 2

Region 5

Region 3

Region 1
My preferred products form is:
(Please rank in order with the numbers 1-7, with 1 being your most preferred product.)

Most preferred product choices

Dry Leaf    Vaporization cartridges/pods    Tinctures    RSO syringes    Topicals    Concentrates    Capsules
My preferred products form is:
(Please rank in order with the numbers 1-7, with 1 being your most preferred product.)

Second most preferred product choices

Dry Leaf  Vaporization cartridges/pods  Tinctures  RSO syringes  Topicals  Concentrates  Capsules
Program Feedback Survey

My preferred products form is:
(Please rank in order with the numbers 1-7, with 1 being your most preferred product.)

Third most preferred product choices

Dry Leaf  Vaporization Cartridges/pods  Tinctures  RSO syringes  Topicals  Concentrates  Capsules
Program Feedback Survey

I feel informed about the different forms of medical marijuana and how to use them.
Program Feedback Survey

I would like to have education on:
(Choose all that apply.)

- Product forms
- Differences between strains
- Understanding cannabinoids and terpenes
- Understanding the safety and testing requirements for the MM program
- Other (Please specify.)

![Bar Graph Showing Education Preferences](chart)
My preferred method for learning about medical marijuana is:
(Please rank in order with numbers 1-6, with 1 being your most preferred method.)

Of the 3,083 respondents who answered this question, 2,076 chose reading website content as their most preferred method of learning about medical marijuana.
Program Feedback Survey

What are your patient needs regarding medical marijuana strains? (Select all that apply.)

- More hybrid (balanced) strains: 16%
- More Sativa strains: 13%
- More Indica strains: 18%
- More strains with CBD: 10%
- Produce a wider variety and selection of dry leaf strains: 24%
- Produce a narrower, but more consistent variety of dry leaf strains: 10%
- Other (Please specify.): 9%
What are your patient needs regarding medical marijuana strains? 
(Select all that apply.)

- Produce a wider variety and selection of dry leaf strains
- More strains with CBD
- More Indica strains
- Produce a narrower, but more consistent variety of dry leaf strains
- More Sativa strains
- More hybrid (balanced) strains
What are your patient needs regarding medical marijuana products?
(Select all that apply.)

- 69.95% - Selected dry leaf
- 48.34% - Consistent cannabinoid, terpene, and dosage information on all labels
- 32.15% - Production of more strain-specific products (one strain per product)
- 30.69% - Production of more multi-strain products (multiple similar strains per product)
- 28.82% - Better patient education/inserts/pamphlets on the product, strain, device, etc.
Program Feedback Survey

How many dispensaries are you willing to visit to find the products you need to meet your needs?
Do you look at dispensary menus online before you visit?

- Yes: 100.00%
- No: 0.00%

Pennsylvania Department of Health
Program Feedback Survey

In general, are you satisfied with the selection of products at Pa. dispensaries?

Responses

- Very satisfied
- Somewhat satisfied
- Somewhat dissatisfied
- Very dissatisfied
In general, are you satisfied with the selection of products at Pa. dispensaries?

Very satisfied

Somewhat satisfied

Somewhat dissatisfied

Very dissatisfied

Region 6

Region 4

Region 2

Region 5

Region 3

Region 1

Pennsylvania Department of Health
If you stopped using medical marijuana, please tell us why.
(Select all that apply)

- 61.11% of respondents said they are unable to afford medical marijuana.
- 44.49% said they have not been able to find a consistent supply of the product(s) they need for their condition.
- 41.85% said they stopped because medical marijuana is not covered by health insurance.
- 21.65 said they were concerned about their legal protections under Act 16.

Although the regional data was mostly consistent, in the Southwest and Southcentral regions, over 67% of respondents said they are unable to afford medical marijuana.

While just between 57% and 60% in Southeast, Northwest, Northcentral and Northeast said they are unable to afford medical marijuana.
Today’s Meeting

• New Business
  - Presentation of the DOH Survey
  - Vaping Related Illnesses
  - Upcoming Research Summit
  - Serious Medical Conditions
Medical Marijuana Program Updates

- Patients and caregivers
- Physicians
- Growers/processors and dispensaries
- Chapter 20
## Serious Medical Conditions

<table>
<thead>
<tr>
<th>Serious Medical Condition</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe chronic or intractable pain of neuropathic origin or severe chronic or intractable pain.</td>
<td>45.02%</td>
</tr>
<tr>
<td>Anxiety Disorders.</td>
<td>14.94%</td>
</tr>
<tr>
<td>Post-traumatic stress disorder.</td>
<td>12.33%</td>
</tr>
<tr>
<td>Cancer, including remission therapy.</td>
<td>6.47%</td>
</tr>
<tr>
<td>Neuropathies.</td>
<td>6.28%</td>
</tr>
<tr>
<td>Opioid use disorder for which conventional therapeutic interventions are contraindicated or ineffective, or for which adjunctive therapy is indicated in combination with primary therapeutic interventions.</td>
<td>3.01%</td>
</tr>
<tr>
<td>Damage to the nervous tissue of the central nervous system (brain-spinal cord) with objective neurological indication of intractable spasticity, and other associated neuropathies.</td>
<td>2.12%</td>
</tr>
<tr>
<td>Inflammatory bowel disease.</td>
<td>2.00%</td>
</tr>
<tr>
<td>Multiple sclerosis.</td>
<td>1.56%</td>
</tr>
<tr>
<td>Epilepsy.</td>
<td>1.20%</td>
</tr>
<tr>
<td>Crohn’s disease.</td>
<td>1.16%</td>
</tr>
<tr>
<td>Autism.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Glaucoma.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Positive status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Parkinson’s disease.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Intractable seizures.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Dyskinetic and spastic movement disorders.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Neurodegenerative diseases.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Tourette Syndrome.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Sickle cell anemia.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Terminal illness.</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Huntington’s disease.</td>
<td>&lt; 1%</td>
</tr>
</tbody>
</table>